Skip to content
Marketing Advertising, Medical Health Aged Care

GMHBA renews sponsorship deal with Geelong Cats

GMHBA 2 mins read

Tuesday 18 July 2023

GMHBA has renewed its partnership with the Geelong Cats, signing a contract extending club sponsorship for a further four years until November 2027 and retaining naming rights to GMHBA Stadium.

Having first joined forces in 2017, the two organisations share a rich history, founded and operating on Wadawurrung Land of Geelong in regional Victoria, and are committed to their promotion of a healthy lifestyle and strong community values.

As part of the ongoing partnership, player ambassadors will participate in a range of GMHBA community events and activities, including an annual Kids’ Clinic at the GMHBA Stadium. The clinic gives up to 200 members the chance to do a skills training session and meet their favourites players.

GMHBA will continue to align with the Geelong’s AFL Health Update, a weekly medical update following each round of the men’s season delivered to Cats members and fans from General Manager of Football Simon Lloyd.

The popular GMHBA Fan Portal, a world-first, unique viewing experience, will continue to offer exclusive access to GMHBA members and pre-game activations will bring health services to life, with the opportunity to win tickets to home games and even the AFL Grand Final.

GMHBA CEO David Greig said the partnership enabled GMHBA to connect with the Geelong community, with a refreshed game day experience to launch in 2024 to celebrate the ongoing commitment.

“The Geelong Cats are a trusted and respected organisation that we are proud to share a long-term partnership with, demonstrating our commitment to improving the health and wellbeing of our members, customers and the communities in which we operate,” he said.

“A benefit of being local partners means we are the only brand sponsor in the AFL to offer on ground activations at every home game and we’re excited to make these even more interactive in 2024.”

GMHBA Chief Marketing Officer Helen Stevens added: “As a regionally based, not-for-profit health insurer, GMHBA is deeply committed to contributing to the communities in which we operate, a sentiment shared by the Geelong Football Club. This alignment is the foundation of our partnership. We are proud to continue to support the Club over the next four years, as we continue to grow our national footprint.” 

Geelong Cats Chief Executive Officer Steve Hocking welcomed the partnership renewal.

“We’re excited to continue our partnership with GMHBA, as two iconic Geelong organisations, the Cats and GMHBA have strong ties in the region and are committed to growing strong and meaningful connections in the community together,” he said.

 

“We look forward to the next four years of the partnership and we thank GMHBA for their ongoing commitment to our Club, members, fans, and the wider Geelong community.”

 

 


About us:

About us

GMHBA is an Australian not for profit health insurance and care company. We have served the community since 1934, and with 85 years’ experience, we have become Australia’s leading regionally based private health insurers.

Through our personalised approach and exceptional customer service, we put the health and wellbeing of our members and communities first. Our approach is guided by our philosophy, Healthier Together and decisions are made with our members first and foremost in mind.


Contact details:

Note to editors: High resolution images available

For all GMHBA media enquiries please contact GMHBA Head of Corporate Communications Meg Rayner on 0458 418 823 or [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.